These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 26917592)

  • 1. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
    Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
    Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
    King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
    Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
    Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
    Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for differential neutralization of ebolaviruses.
    Bale S; Dias JM; Fusco ML; Hashiguchi T; Wong AC; Liu T; Keuhne AI; Li S; Woods VL; Chandran K; Dye JM; Saphire EO
    Viruses; 2012 Apr; 4(4):447-70. PubMed ID: 22590681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
    Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
    Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
    Shedlock DJ; Bailey MA; Popernack PM; Cunningham JM; Burton DR; Sullivan NJ
    Virology; 2010 Jun; 401(2):228-35. PubMed ID: 20304456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
    Reynard O; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.
    Bornholdt ZA; Ndungo E; Fusco ML; Bale S; Flyak AI; Crowe JE; Chandran K; Saphire EO
    mBio; 2016 Feb; 7(1):e02154-15. PubMed ID: 26908579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
    Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
    Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
    Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
    Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.
    Koellhoffer JF; Chen G; Sandesara RG; Bale S; Saphire EO; Chandran K; Sidhu SS; Lai JR
    Chembiochem; 2012 Nov; 13(17):2549-57. PubMed ID: 23111988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
    Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
    Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.
    Marzi A; Yoshida R; Miyamoto H; Ishijima M; Suzuki Y; Higuchi M; Matsuyama Y; Igarashi M; Nakayama E; Kuroda M; Saijo M; Feldmann F; Brining D; Feldmann H; Takada A
    PLoS One; 2012; 7(4):e36192. PubMed ID: 22558378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.
    Olal D; Kuehne AI; Bale S; Halfmann P; Hashiguchi T; Fusco ML; Lee JE; King LB; Kawaoka Y; Dye JM; Saphire EO
    J Virol; 2012 Mar; 86(5):2809-16. PubMed ID: 22171276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model.
    Li W; Yang W; Liu X; Zhou W; Wang S; Wang Z; Zhao Y; Feng N; Wang T; Wu M; Ge L; Xia X; Yan F
    Emerg Microbes Infect; 2024 Dec; 13(1):2392651. PubMed ID: 39155772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors.
    Fan P; Chi X; Liu G; Zhang G; Chen Z; Liu Y; Fang T; Li J; Banadyga L; He S; Yu C; Qiu X; Chen W
    MAbs; 2020; 12(1):1742457. PubMed ID: 32213108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.